FilingSEC EDGAR8-K
Precision BioSciences Announces Positive Phase 1 Data for PBGENE-HBV and Plans for Phase 2
· SEC accepted
StagePhase 2 Preparation
Filing content
The company confirmed cccDNA elimination and pgRNA reduction in its Phase 1 PBGENE-HBV study and plans to initiate a global Phase 2 trial in the first quarter of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…